1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Huntington Disease - Drugs In Development, 2022, provides an overview of the Huntington Disease (Central Nervous System) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. HD is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Huntington Disease - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Huntington Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Huntington Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Huntington Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 15, 8, 2, 69, 39 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 22 and 7 molecules, respectively.
Huntington Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Huntington Disease (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Huntington Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Huntington Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Huntington Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Huntington Disease (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Huntington Disease (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Huntington Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Huntington Disease - Overview
- Huntington Disease - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Huntington Disease - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Huntington Disease - Companies Involved in Therapeutics Development
- Huntington Disease - Drug Profiles
- Huntington Disease - Dormant Projects
- Huntington Disease - Discontinued Products
- Huntington Disease - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- Number of Products under Development for Huntington Disease, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Huntington Disease - Dormant Projects, 2022
- Huntington Disease - Discontinued Products, 2022
- Number of Products under Development for Huntington Disease, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Acen Regenerative Medicine Sci-Tech Co Ltd
- AFFiRiS AG
- Alchemab Therapeutics Ltd
- Alkermes Plc
- Alnylam Pharmaceuticals Inc
- Alsonex Pty Ltd
- Anima Biotech Inc
- ANLBio Co Ltd
- Annexon Inc
- Annji Pharmaceutical Co Ltd
- AOP Health
- ARMGO Pharma Inc
- ArunA Bio Inc
- Arvinas Inc
- Asahi Kasei Pharma Corp
- Asdera LLC
- Asklepios BioPharmaceutical Inc
- Astellas Pharma Inc
- Atalanta Therapeutics Inc
- Avergen Pharmaceuticals GmbH
- Azevan Pharmaceuticals Inc
- Berg LLC
- Bionaut Labs Inc
- Biorchestra Co Ltd
- Blade Therapeutics Inc
- BrainStorm Cell Therapeutics Inc
- Brainvectis SAS
- Cellavita Pesquisa Cientifica Ltda
- Ceptur Therapeutics Inc
- Chaperone Pharma BV
- Chaperone Therapeutics Inc
- Chong Kun Dang Pharmaceutical Corporation
- Cleave Therapeutics Inc
- Collaborative Medicinal Development LLC
- DanPET AB
- Dystrogen Therapeutics SA
- Eikonoklastes Therapeutics Inc
- Emerald Health Pharmaceuticals Inc
- Enzerna Biosciences LLC
- Exicure Inc
- Exopharm Ltd
- F. Hoffmann-La Roche Ltd
- Forest Hills Partners Hong Kong Ltd
- Fundamental Pharma Gmbh
- Gatehouse Bio
- Immungenetics AG
- Incisive Genetics Inc
- InnoMedica Holding AG
- Janusq LLC
- KeifeRx LLC
- Krisani Bio Sciences Pvt Ltd
- Locanabio Inc
- Loqus23 Therapeutics Ltd
- Luye Pharma Group Ltd
- Malachite Innovations Inc
- Medesis Pharma SA
- MindImmune Therapeutics Inc
- Mitochon Pharmaceuticals Inc
- Mitoconix Bio Ltd
- Mitokinin LLC
- MitoRx Therapeutics Ltd
- MMJ International Holdings Corp
- Modelis Inc
- NeuBase Therapeutics Inc
- NeuExcell Therapeutics Inc
- Neurano Bioscience
- Neurimmune Holding AG
- Neurodon LLC
- NeuroNascent Inc
- Neuropore Therapies Inc
- Nevrox Ltd
- New World Laboratories Inc
- NLS Pharmaceutics AG
- Novartis AG
- Nuredis Inc
- Ophidion Inc
- Origami Therapeutics Inc
- Oryzon Genomics SA
- Oxalys Pharmaceuticals Inc
- Paramag Biosciences
- Passage Bio Inc
- PCG-Biotech Co Ltd
- PharmatrophiX Inc
- PolyCore Therapeutics LLC
- Priavoid GmbH
- Prilenia Therapeutics Development Ltd
- Primary Peptides Inc
- ProMIS Neurosciences Inc
- ProQR Therapeutics NV
- Prous Institute for Biomedical Research SA
- PTC Therapeutics Inc
- PurMinds NeuroPharma Inc
- Reata Pharmaceuticals Inc
- reMYND NV
- ReNeuron Group Plc
- Resilio Therapeutics LLC
- ResQ Biotech
- Retrotope Inc
- Sage Therapeutics Inc
- Sana Biotechnology Inc
- Seelos Therapeutics, Inc.
- Seneb BioSciences Inc
- Shinkei Therapeutics LLC
- SOLA Biosciences LLC
- SOM Biotech SL
- Sosei Group Corp
- Spark Therapeutics Inc
- Stealth BioTherapeutics Corp
- Suven Life Sciences Ltd
- T3D Therapeutics Inc
- Takeda Pharmaceutical Co Ltd
- Teitur Trophics ApS
- Teva Pharmaceutical Industries Ltd
- Trailhead Biosystems Inc
- TreeFrog Therapeutics SAS
- Triplet Therapeutics Inc
- Ultragenyx Pharmaceutical Inc
- UniQure NV
- Vaccinex Inc
- Vanqua Bio Inc
- Vico Therapeutics BV
- Vivoryon Therapeutics NV
- Voyager Therapeutics Inc
- Vybion Inc
- Wave Life Sciences Ltd
- ZyVersa Therapeutics Inc
